A REVIEW ARTICLE ON FORMULATION AND EVALUATION TECHNIQUES OF MOUTH DISSOLVING TABLET INCORPORATING LIPOSOMES AND NIOSOMES ENHANCED DRUG DELIVERY

The goal of this study is to create oral mouth dissolving tablets (MDTs) that include liposomes and niosomes as vesicular drug delivery systems in order to increase drug bioavailability and therapeutic effectiveness. Liposomes, which are made of phospholipids, and niosomes, which are made of non-ionic surfactants, are carriers that increase medication solubility and permeability while also shielding the drug from enzymatic and acidic breakdown when taken orally. Oral cavity disintegrating tablets offer quick disintegration and dissolution, which helps enhance patient adherence, especially for medications with low water solubility and first-pass metabolism. The goal of these vesicular systems in the designed MDTs is to enhance drug absorption by extending drug release, increasing drug stability, and bypassing the hepatic first-pass effect, all of which lead to greater bioavailability. Evaluation criteria often include drug entrapment efficacy, particle size, in vitro drug release, disintegration time, and in vivo pharmacokinetic studies that show enhanced systemic bioavailability when compared to traditional dosage forms. These formulations have promise for improved therapeutic effectiveness with drugs that are not very soluble and those that need a rapid onset of action. This strategy combines the benefits of oral disintegrating tablets with the targeted and sustained release capabilities of liposomes and niosomes, demonstrating promise for improving the effectiveness of oral drug delivery.